Last Updated: September 23, 2026

Patent: 10,232,041

✉ Email this page to a colleague

Summary for Patent: 10,232,041

Title:	Combination of lenalidomide and polypeptide construct, and uses thereof
Abstract:	Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
Inventor(s):	Sarah L. Pogue, David S. Wilson, Anthony Gerard Doyle, Collette Jane Behrens
Assignee:	Teva Pharmaceuticals Australia Pty Ltd
Application Number:	US15/420,152
Patent Claims:	see list of patent claims

Details for Patent 10,232,041

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	18-Sep-14	10,232,041	2037-01-31
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	4-Sep-20	10,232,041	2037-01-31
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,232,041

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2015265624	⤷ Start Trial
Brazil	112016025437	⤷ Start Trial
Canada	2945902	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.